Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2013

Conditions
GlioblastomaGliosarcoma
Interventions
DRUG

Avastin

Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.

DRUG

Bortezomib

Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.

Trial Locations (1)

27710

Duke University Health System, Durham

All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER